Doxorubicin PhaRes - Injection Doxorubicin Hydrochloride - 2mg/ml 1 50mg Vial(s) / 50mg Vial ZAS Corporation Introduction: Doxorubicin PhaRes is used in the treatment of some kinds of cancer. It is also used in the treatment of breast cancer, where there is an increased cardiac risk. It can be used on its own, or sometimes given together with certain other medicines as part of combination chemotherapy. Doxorubicin PhaRes can be used in both adults and children. It is given as injection into vein with extreme caution by a qualified medical professional. Your doctor will decide what dose is necessary and how often you need to take it. This will depend on what you are being treated for... Uses of Doxorubicin PhaRes: Cancer Side effects of Doxorubicin PhaRes: NauseaVomitingRashWeaknessLow blood plateletsFatigueFeverDecreased white blood cell count (neutrophils)Loss of appetiteAnemia (low number of red blood cells)ConstipationStomatitis (Inflammation of the mouth)DiarrheaPainful blisters on hands and feet How to use Doxorubicin PhaRes: Your doctor or nurse will give you this medicine. Kindly do not self administer. How Doxorubicin PhaRes works: Doxorubicin PhaRes is an anti-cancer medication. It works by damaging the genetic material (DNA) of the cancer cells and stops their growth and multiplication. Indication: AIDS-related Kaposi's sarcoma, Ovarian carcinoma, Metastatic breast carcinoma, bladder carcinoma Adult Dose: Intravenous As Doxorubicin liposomal Kaposi's Sarcoma Indicated for AIDS-related Kaposi’s sarcoma in patients after failure of prior systemic chemotherapy or intolerance to such therapy 20 mg/m² IV q3Weeks Ovarian Cancer Indicated for ovarian cancer in patients whose disease has progressed or recurred after platinum-based chemotherapy 50 mg/m² IV q4Weeks x 4 courses minimum Multiple Myeloma Indicated in combination with bortezomib for multiple myeloma in patients who have not previously received bortezomib and have received at least 1 prior therapy 30 mg/m² IV on day 4 following bortezomib 1.3 mg/m² on days 1, 4, 8 & 11 q3Weeks Metastatic breast cancer... Child Dose: Safety and efficacy not established Renal Dose: Renal Impairment Dose adjustment not necessary Contraindication: Cardiac disease, neonates, pregnancy and lactation, prior irradiation to mediastinum. IM/SC admin. Severe myelosuppression due to previous treatment with antitumour agents or radiotherapy. Mode of Action: Doxorubicin is a cytotoxic anthracycline antibiotic. The cytotoxic action results from its binding to DNA and inhibition of nucleic acid synthesis. Doxorubicin has been shown to produce regression in a variety of disseminated malignancies. Precaution: Elderly, children, hepatic impairment. Monitor blood counts and ECG. Lactation: Enters breast milk/not recommended Side Effect: >10% Kaposi's Sarcoma Anemia (>50%),Thrombocytopenia (>50%),Neutropenia (10-50%),Anemia (18.2%),Nausea (17%) Ovarian cancer >25% Hand-foot syndrome (50%),Nausea (46%),Stomatitis (41%),Asthenia (40.2%),Vomiting (32.6%),Rash (28%),Constipation (>25%),Abdominal pain (>25%) Ovarian cancer 10-25% Fever (21.3%),Anorexia (20%),Diarrhea (20%),Peripheral edema,Dyspepsia,Pharyngitis,Dyspnea,Alopecia 1-10% Kaposi's Sarcoma 5-10% Asthenia (9.9%),Fever (9.1%),Diarrhea (7.8%),Vomiting (7.8%),Stomatitis (6.8%),Rash (1-5%),Alopecia (1-5%),Increased alkaline phosphatase Kaposi's Sarcoma 1-5% Hand-foot syndrome (3.4%),Hypotension,Tachycardia,Dyspnea,Hemolysis,Rash Ovarian cancer (selected) Neutropenia (13.3%),Anemia (0.4-5.4%),Thrombocytopenia (1.3%) <1% Abscess,Acute myeloid leukemia,Cardiomegaly,Cardiomyopathy,Erythema nodosum,Hyperkalemia,Hyperuricemia,Ketosis Potentially Fatal: Bone marrow suppression, cardiotoxicity. Pregnancy Category Note: Pregnancy Category: D Lactation: Enters breast milk/not recommended Interaction: Doxorubicin interacts with a number of other drugs e.g. antibiotics (aminoglycosides), steroids, aminophylline and propranolol. Potentially Fatal: Cholestasis induced by mercaptopurine may be potentiated by concurrent administration of the drug. Toxicity may be increased if streptozocin is given concurrently.